K-C Cheng1, Cheng Li, Annette S Uss. 1. Schering-Plough Research Institute, Drug Metabolism and Pharmacokinetics Submissions, Drug Safety and Metabolism, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. kuo-chi.cheng@spcorp.com
Abstract
BACKGROUND: Over the past decade, the use of drug metabolism and pharmacokinetic (DMPK) parameters to optimize selection of candidates for drug development has become one of the primary focuses of research organizations involved in new drug discovery. OBJECTIVE: This review will focus on the feasibility of predicting human absorption using data from a cultured Caco-2 cell system and non-clinical animals. METHODS: In-house Caco-2 permeability data were compared with human absorption data from the literature. Animal absorption data obtained from current literature were also compared with human data. RESULTS/ CONCLUSION: Using a combination of rapid in-vivo and in-vitro DMPK screens on a large array of compounds during the lead optimization process has resulted in the streamlined development of compounds that have acceptable DMPK properties. Since it is well recognized that human intestinal absorption cannot be precisely predicted by a single screening assay, it is important to utilize various in-vitro and in-vivo non-clinical studies during lead optimization in drug discovery.
BACKGROUND: Over the past decade, the use of drug metabolism and pharmacokinetic (DMPK) parameters to optimize selection of candidates for drug development has become one of the primary focuses of research organizations involved in new drug discovery. OBJECTIVE: This review will focus on the feasibility of predicting human absorption using data from a cultured Caco-2 cell system and non-clinical animals. METHODS: In-house Caco-2 permeability data were compared with human absorption data from the literature. Animal absorption data obtained from current literature were also compared with human data. RESULTS/ CONCLUSION: Using a combination of rapid in-vivo and in-vitro DMPK screens on a large array of compounds during the lead optimization process has resulted in the streamlined development of compounds that have acceptable DMPK properties. Since it is well recognized that human intestinal absorption cannot be precisely predicted by a single screening assay, it is important to utilize various in-vitro and in-vivo non-clinical studies during lead optimization in drug discovery.
Authors: Diego Marescotti; Giuseppe Lo Sasso; Diego Guerrera; Kasper Renggli; Pedro A Ruiz Castro; Romain Piault; Vincent Jaquet; Fabian Moine; Karsta Luettich; Stefan Frentzel; Manuel C Peitsch; Julia Hoeng Journal: Front Pharmacol Date: 2021-04-16 Impact factor: 5.810
Authors: Johannes Schwerk; Mario Köster; Hansjörg Hauser; Manfred Rohde; Marcus Fulde; Mathias W Hornef; Tobias May Journal: PLoS One Date: 2013-08-05 Impact factor: 3.240